707 related articles for article (PubMed ID: 31070059)
1. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.
Albadari N; Deng S; Li W
Expert Opin Drug Discov; 2019 Jul; 14(7):667-682. PubMed ID: 31070059
[No Abstract] [Full Text] [Related]
2. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.
Wigerup C; Påhlman S; Bexell D
Pharmacol Ther; 2016 Aug; 164():152-69. PubMed ID: 27139518
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.
Burroughs SK; Kaluz S; Wang D; Wang K; Van Meir EG; Wang B
Future Med Chem; 2013 Apr; 5(5):553-72. PubMed ID: 23573973
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors.
Xia Y; Choi HK; Lee K
Eur J Med Chem; 2012 Mar; 49():24-40. PubMed ID: 22305612
[TBL] [Abstract][Full Text] [Related]
6. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
Ajith TA
J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule inhibitors of the HIF pathway and synthetic lethal interactions.
Jones DT; Harris AL
Expert Opin Ther Targets; 2012 May; 16(5):463-80. PubMed ID: 22512262
[TBL] [Abstract][Full Text] [Related]
8. Targeting HIF-2α as therapy for advanced cancers.
Murugesan T; Rajajeyabalachandran G; Kumar S; Nagaraju S; Jegatheesan SK
Drug Discov Today; 2018 Jul; 23(7):1444-1451. PubMed ID: 29753878
[TBL] [Abstract][Full Text] [Related]
9. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
Yu T; Tang B; Sun X
Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-inducible factor (HIF)-3alpha is subject to extensive alternative splicing in human tissues and cancer cells and is regulated by HIF-1 but not HIF-2.
Pasanen A; Heikkilä M; Rautavuoma K; Hirsilä M; Kivirikko KI; Myllyharju J
Int J Biochem Cell Biol; 2010 Jul; 42(7):1189-200. PubMed ID: 20416395
[TBL] [Abstract][Full Text] [Related]
11. Cell-permeable hypoxia-inducible factor-1 (HIF-1) antagonists function as tumor radiosensitizers.
Shi M; Guo XT; Shu MG; Chen FL; Li LW
Med Hypotheses; 2007; 69(1):33-5. PubMed ID: 17280792
[TBL] [Abstract][Full Text] [Related]
12. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells.
Palayoor ST; Tofilon PJ; Coleman CN
Clin Cancer Res; 2003 Aug; 9(8):3150-7. PubMed ID: 12912967
[TBL] [Abstract][Full Text] [Related]
13. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.
Wilczynski J; Duechler M; Czyz M
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):301-7. PubMed ID: 21625847
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Description of Hypoxia-inducible Factor 2α Inhibitors as Anticancer Agents: A Mini-review.
Lu H; Zhu Y; Liu W; Yan Y; Jiang X; Wang Q; Zhao Y; He M; Wei M
Curr Med Chem; 2023; 30(25):2835-2849. PubMed ID: 36043744
[TBL] [Abstract][Full Text] [Related]
15. HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.
Jarman EJ; Ward C; Turnbull AK; Martinez-Perez C; Meehan J; Xintaropoulou C; Sims AH; Langdon SP
Breast Cancer Res; 2019 Jan; 21(1):10. PubMed ID: 30670058
[TBL] [Abstract][Full Text] [Related]
16. Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia.
Aquino-Gálvez A; González-Ávila G; Delgado-Tello J; Castillejos-López M; Mendoza-Milla C; Zúñiga J; Checa M; Maldonado-Martínez HA; Trinidad-López A; Cisneros J; Torres-Espíndola LM; Hernández-Jiménez C; Sommer B; Cabello-Gutiérrez C; Gutiérrez-González LH
Oncol Rep; 2016 Jan; 35(1):577-83. PubMed ID: 26548300
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-inducible factors and sphingosine 1-phosphate signaling.
Cuvillier O; Ader I
Anticancer Agents Med Chem; 2011 Nov; 11(9):854-62. PubMed ID: 21707486
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of hypoxia-inducible factor-2 involved in chemo/radioresistance in solid tumors.
Zhao J; Du F; Luo Y; Shen G; Zheng F; Xu B
Cancer Treat Rev; 2015 Jul; 41(7):623-33. PubMed ID: 25981453
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Zhao D; Zhai B; He C; Tan G; Jiang X; Pan S; Dong X; Wei Z; Ma L; Qiao H; Jiang H; Sun X
Cell Signal; 2014 May; 26(5):1030-9. PubMed ID: 24486412
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
